Poor
Not Aligned
Patient Risk:
Medium
Summary
Several claims conflict with the provided label (mechanism of action) and many efficacy/safety/administration/monitoring assertions are unsupported by the provided prescribing information excerpts. The pediatric prescribing claim also overreaches the label (pediatric safety/effectiveness not established).
Category Scores
Accurate Statements
Trogarzo is used in combination with other antiretroviral medications.
Supported by Section 1 INDICATIONS AND USAGE ("in combination with other antiretroviral(s)").
The usual dosage for Trogarzo is an intravenous infusion every two weeks.
Partially supported by Section 2.1 (maintenance dose 800 mg every 2 weeks; administered as diluted IV infusion or undiluted IV push).
Unsupported Statements
Trogarzo blocks the HIV fusion protein, preventing the virus from entering host cells.
Not supported; label describes a CD4-directed post-attachment HIV-1 inhibitor rather than fusion-protein blocking/entry prevention.
Trogarzo is prescribed for adults and children with HIV-1 infection.
Unsupported/overreaching: label indication is for heavily treatment-experienced adults (Section 1) and pediatric safety/effectiveness have not been established (Section 8.4).
Trogarzo is prescribed for patients who have been treated with multiple antiretroviral therapies (ART).
Partially supported indirectly via 'heavily treatment-experienced,' but the claim is not explicitly stated in the provided label text as 'multiple ART' wording.
Trogarzo is prescribed for patients with at least one virus resistance mutation.
Not supported in provided label excerpts; label uses 'multidrug resistant' and 'failing their current antiretroviral regimen' (Section 1) without stating 'at least one virus resistance mutation.'
Trogarzo is prescribed for patients with a suboptimal response to other treatments.
Not supported as worded; label states failing their current antiretroviral regimen (Section 1) rather than 'suboptimal response.'
Trogarzo is usually used as a last resort.
Not supported by the provided label excerpts.
Trogarzo is used under close medical supervision.
Not supported by the provided label excerpts (no explicit 'close medical supervision' language provided).
When used in combination with other antiretroviral therapies, Trogarzo significantly reduces viral load.
Not supported by the provided label excerpts (no efficacy/viral load outcome text provided).
When used in combination with other antiretroviral therapies, Trogarzo improves T-cell count.
Not supported by the provided label excerpts (no T-cell efficacy outcome text provided).
When used in combination with other antiretroviral therapies, Trogarzo increases the chances of suppressing the virus.
Not supported by the provided label excerpts (no virus suppression outcome text provided).
Trogarzo effectiveness may vary depending on the individual patient's condition, viral load, and treatment experience.
Not supported by provided label excerpts.
Trogarzo should be administered in a healthcare setting by healthcare professionals experienced in the management of HIV-1 infection.
Not supported by the provided label excerpts.
Regular medical check-ups, viral load monitoring, and blood work are necessary to assess effectiveness of Trogarzo.
Not supported by the provided label excerpts.
Regular medical check-ups, viral load monitoring, and blood work are necessary to manage any potential side effects.
Not supported by the provided label excerpts.
Trogarzo infrequently reported risks include allergic reactions.
Hypersensitivity (including infusion-related and anaphylactic reactions) is described, but 'infrequently' and 'allergic reactions' as phrased are not explicitly supported in the provided excerpt.
Trogarzo infrequently reported risks include increased risk of certain types of cancer.
Not supported by the provided label excerpts.
Trogarzo infrequently reported risks include kidney or liver damage.
Not supported as clinical harms; only laboratory abnormalities markers (e.g., creatinine/bilirubin elevations) are shown in the provided excerpt, without stating 'kidney or liver damage' or 'infrequently' framing.
Clinical trials have demonstrated the efficacy and safety profile of Trogarzo.
Safety-related trial experience is described, but explicit efficacy outcome support is not present in the provided excerpts.
Trogarzo was approved for use by the U.S. Food and Drug Administration (FDA) in 2018.
Not supported by the provided label excerpts (no approval year given).
Contradictions
Low
AI Statement
Trogarzo (ibalizumab-uiyk) is an HIV fusion inhibitor.
Label Reference
Label mechanism: TROGARZO is a CD4-directed post-attachment HIV-1 inhibitor (Section 11 DESCRIPTION).
Low
AI Statement
Trogarzo blocks the HIV fusion protein, preventing the virus from entering host cells.
Label Reference
Label does not describe fusion-protein blocking; it describes CD4-directed post-attachment inhibition (Sections 11 DESCRIPTION; 12 CLINICAL PHARMACOLOGY 12.1).
Important Omissions
Contraindications section content (Section 4) was not evaluated; several safety-critical statements in the extracted claims (e.g., supervision/monitoring) may depend on label contraindications/warnings not included in the provided excerpts.
Importance:
Moderate
Warnings/precautions beyond hypersensitivity (e.g., immune reconstitution inflammatory syndrome) were not assessed; extracted claims about monitoring/side-effect management may be materially incomplete without those warning details.
Importance:
Moderate
Specific administration safety instructions for infusion vs IV push (rate, monitoring during administration, handling) were not provided in the excerpts; extracted claim about healthcare setting/credentialing is therefore not label-supported.
Importance:
Moderate
Safety Assessment
Potential Patient Risk:
Medium
Unsupported claims about pediatric prescribing, mechanism, and required monitoring/administration setting could lead to inaccurate labeling interpretation. The response also includes unsupported efficacy statements (viral load/T-cell) that are not substantiated in the provided excerpts.
Regulatory Assessment
| On Label |
No |
| Off-label Discussion |
No |
| Promotes Unapproved Use |
No |
| Hallucination Risk |
Medium |
Recommendation
Not Aligned
Primary Issue
Multiple mechanism and population/monitoring assertions are not supported or are contradicted by the provided label excerpts; pediatric prescribing is overextended beyond 'safety and effectiveness have not been established.'
Suggested Improvement
Restrict statements to the provided label language: describe TROGARZO as CD4-directed post-attachment inhibition; align indication to heavily treatment-experienced adults with multidrug resistant HIV-1 failing current regimen; remove pediatric prescribing as established; remove unsupported viral load/T-cell/last-resort/supervision/monitoring necessity claims unless supported by additional label sections.